(PDF) P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.585

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-95 Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients With ROS1 Rearrangement——A Single Chinese Cancer Institute Experience

Journal of Thoracic Oncology

Respiratory Medicine

English

Feasibility of Continuing Crizotinib Therapy After RECIST-PD in Advanced Non-Small Cell Lung Cancer Patients With ALK/ROS-1 Mutations

Journal of Cancer

English

Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer With ALK-rearrangement: A Brief Report

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-05 Metformin in Combination With Crizotinib for the Treatment of EML4-ALK+ Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience From Turkey

Journal of Thoracic Oncology

Respiratory Medicine

English

Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma

Clinical Lung Cancer

Cancer Research

Respiratory Medicine

English

Outcomes of ALK Positive Lung Cancer Patients Treated With Crizotinib or Second-Generation ALK Inhibitor: A Monoinstitutional Experience

English

A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib

Journal of Thoracic Oncology

Respiratory Medicine

English